Description

TELMISIGN TRIO TABLET is a comprehensive antihypertensive solution that combines three pharmacologically complementary agents to provide optimal blood pressure control in patients who require multi-drug therapy.

• Telmisartan: An angiotensin II receptor blocker (ARB) that relaxes blood vessels by preventing the action of a hormone that tightens blood vessels, thereby lowering blood pressure.

• Amlodipine: A calcium channel blocker that widens blood vessels and improves blood flow by reducing the heart’s workload.

• Hydrochlorothiazide (HCTZ): A thiazide diuretic that helps eliminate excess salt and water from the body to further reduce blood pressure and fluid retention.

This triple-combination therapy offers superior antihypertensive efficacy, especially for patients with:

• Stage 2 or resistant hypertension

• High cardiovascular risk profiles

• Diabetes or chronic kidney disease

• Inadequate response to monotherapy or dual therapy

• Telmisartan blocks vasoconstrictor effects of angiotensin II.

• Amlodipine inhibits calcium influx in vascular smooth muscle.

• Hydrochlorothiazide promotes diuresis and sodium excretion.

Together, they provide a multi-targeted approach to control blood pressure, reduce fluid overload, improve heart function, and protect vital organs like the brain, kidneys, and heart.

• Effective triple-drug therapy in one convenient daily dose

• Improved patient compliance and therapeutic adherence

• Fast-acting and long-lasting blood pressure control

• Reduces the risk of stroke, heart attack, and kidney damage

• Suitable for long-term cardiovascular disease prevention

• Essential hypertension requiring three-drug combination therapy

• Hypertension with target organ damage

• Secondary prevention in patients with cardiovascular comorbidities

• Taken once daily with or without food, as directed by a healthcare provider

• Blood pressure should be monitored regularly during therapy

• Dosage adjustments may be required in elderly patients or those with renal impairment

• Not recommended during pregnancy or in patients with severe hepatic or renal dysfunction

• Monitor electrolytes, kidney function, and blood pressure regularly

• Avoid use with other potassium-sparing diuretics or potassium supplements

• Use cautiously in patients with heart failure, diabetes, or gout

TELMISIGN TRIO TABLET is developed and manufactured under stringent quality control systems certified by WHO-GMP, ISO, and other international standards.

It is proudly represented and exported by BLUEPILL EXPRESS, a globally recognized third-party pharmaceutical manufacturer and supplier offering:

• Global regulatory support

• Timely and consistent delivery

• High-quality finished formulations

• Custom labelling and private branding services

BLUEPILL EXPRESS exports to over 40 countries, including regions in:

• Asia

• Africa

• Latin America

• Middle East

• CIS countries

• Europe